Effects of the COVID-19 pandemic on a cohort of patients with vein occlusion.
Rev Clin Esp (Barc)
; 221(10): 587-591, 2021 12.
Article
in English
| MEDLINE | ID: covidwho-1415752
ABSTRACT
BACKGROUND AND OBJECTIVES:
A new coronavirus disease in humans, COVID-19, caused by SARS-CoV-2, emerged in December 2019. It has been associated with the development of thrombotic phenomena. Retinal vein occlusion (RVO) is mainly a consequence of vascular risk factors (VRF). This study aimed to analyze cases of COVID-19 in a cohort of patients with RVO (Valdecilla cohort). PATIENTS ANDMETHODS:
Between December 2008 and December 2020, 429 patients with RVO were attended to in our clinic. Ten patients had COVID-19, one of which did not have VRF or thrombophilia. The remaining nine patients had RVO prior to the infection and VRF, six had carotid atherosclerosis, and four had antiphospholipid syndrome. The infection did not cause thrombotic phenomena in any of them.CONCLUSIONS:
RVO is a rare manifestation of COVID-19. In our cohort of patients with RVO, COVID-19 disease did not lead to thrombotic events.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Retinal Vein Occlusion
/
Antiphospholipid Syndrome
/
Thrombophilia
/
COVID-19
Type of study:
Case report
/
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Rev Clin Esp (Barc)
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS